苏轩堂2022年度报告

UNITEDSTATES SECURITIESANDEXCHANGECOMMISSIONWASHINGTON,D.C.20549 FORM20-F ☐REGISTRATIONSTATEMENTPURSUANTTOSECTION12(b)OR(g)OFTHESECURITIESEXCHANGEACTOF1934 OR ☒ANNUALREPORTPURSUANTTOSECTION13OR15(d)OFTHESECURITIESEXCHANGEACTOF1934 ForthefiscalyearendedMarch31,2023OR ☐TRANSITIONREPORTPURSUANTTOSECTION13OR15(d)OFTHESECURITIESEXCHANGEACTOF1934 Forthetransitionperiodfromto. OR ☐SHELLCOMPANYREPORTPURSUANTTOSECTION13OR15(d)OFTHESECURITIESEXCHANGEACTOF1934 Dateofeventrequiringthisshellcompanyreport:Commissionfilenumber:001-38773ChinaSXTPharmaceuticals,Inc. (ExactnameofRegistrantasSpecifiedinitsCharter) BritishVirginIslands (JurisdictionofIncorporationorOrganization) 178TaidongRdNorth,TaizhouJiangsu,China (AddressofPrincipalExecutiveOffices) FengZhou 178TaidongRdNorth,TaizhouJiangsu,China +86-523-86298290 (Name,Telephone,E-mailand/orFacsimileNumberandAddressofCompanyContactPerson)SecuritiesregisteredortoberegisteredpursuanttoSection12(b)oftheAct: TitleofEachClassNameofEachExchangeOnWhichRegistered Ordinaryshares,parvalueUS$0.08pershareNASDAQCapitalMarket SecuritiesregisteredortoberegisteredpursuanttoSection12(g)oftheAct: None(TitleofClass) SecuritiesforwhichthereisareportingobligationpursuanttoSection15(d)oftheAct: None(TitleofClass) Thenumberofoutstandingsharesofeachoftheissuer’sclassesofcapitalorcommonstockasofMarch31,2023was:11,434,129ordinaryshares,parvalue$0.08pershare. Indicatebycheckmarkiftheregistrantisawell-knownseasonedissuer,asdefinedinRule405oftheSecuritiesAct. Yes☐No☒ Ifthisreportisanannualortransitionreport,indicatebycheckmarkiftheregistrantisnotrequiredtofilereportspursuanttoSection13or15(d)oftheSecuritiesExchangeActof1934. Yes☐No☒ Indicatebycheckmarkwhethertheregistrant(1)hasfiledallreportsrequiredtobefiledbySection13or15(d)oftheSecuritiesExchangeActof1934duringthepreceding12months(orforsuchshorterperiodthattheregistrantwasrequiredtofilesuchreports),and(2)hasbeensubjecttosuchfilingrequirementsforthepast90days. Yes☒No☐ IndicatebycheckmarkwhethertheregistranthassubmittedelectronicallyeveryInteractiveDataFilerequiredtobesubmittedandpostedpursuanttoRule405ofRegulationS-T(§232.405ofthischapter)duringthepreceding12months(orforsuchshorterperiodthattheregistrantwasrequiredtosubmitandpostsuchfiles). Yes☒No☐ Indicatebycheckmarkwhethertheregistrantisalargeacceleratedfiler,anacceleratedfiler,anon-acceleratedfiler,oranemerginggrowthcompany.Seedefinitionof“largeacceleratedfiler,”“acceleratedfiler”and“emerginggrowthcompany”inRule12b-2oftheExchangeAct.(Checkone): Largeacceleratedfiler☐Acceleratedfiler☐Non-acceleratedfiler☒Emerginggrowth company☒ IfanemerginggrowthcompanythatpreparesitsfinancialstatementsinaccordancewithU.S.GAAP,indicatebycheckmarkiftheregistranthaselectednottousetheextendedtransitionperiodforcomplyingwithanyneworrevisedfinancialaccountingstandards†providedpursuanttoSection13(a)oftheExchangeAct.☐ Indicatebycheckmarkwhethertheregistranthasfiledareportonandattestationtoitsmanagement’sassessmentoftheeffectivenessofitsinternalcontroloverfinancialreportingunderSection404(b)oftheSarbanes-OxleyAct(15U.S.C.7262(b))bytheregisteredpublicaccountingfirmthatpreparedorissueditsauditreport.☐ IfsecuritiesareregisteredpursuanttoSection12(b)oftheAct,indicatebycheckmarkwhetherthefinancialstatementsoftheregistrantincludedinthefilingreflectthecorrectionofanerrortopreviouslyissuedfinancialstatements.☐ Indicatebycheckmarkwhetheranyofthoseerrorcorrectionsarerestatementsthatrequiredarecoveryanalysisofincentive-basedcompensationreceivedbyanyoftheregistrant’sexecutiveofficersduringtherelevantrecoveryperiodpursuantto§240.10D-1(b).☐ Indicatebycheckmarkwhichbasisofaccountingtheregistranthasusedtopreparethefinancialstatementsincludedinthisfiling: ☒U.S.GAAP☐InternationalFinancialReportingStandardsasissuedbytheInternationalAccountingStandardsBoard ☐Other If“Other”hasbeencheckedinresponsetothepreviousquestion,indicatebycheckmarkwhichfinancialstatementitemtheregistranthaselectedtofollow:Item17☐Item18☐ Ifthisisanannualreport,indicatebycheckmarkwhethertheregistrantisashellcompany(asdefinedinRule12b-2oftheExchangeAct). Yes☐No☒ CHINASXTPHARMACEUTICALS,INC.FORM20-FANNUALREPORT TABLEOFCONTENTS Page PARTI Item1. IdentityofDirectors,SeniorManagementandAdvisers 3 Item2. OfferStatisticsandExpectedTimetable 3 Item3. KeyInformation 3 Item4. InformationonTheCompany 28 Item4A. UnresolvedStaffComments 50 Item5. OperatingandFinancialReviewandProspects 50 Item6. Directors,SeniorManagementandEmployees 63 Item7. MajorShareholdersandRelatedPartyTransactions 72 Item8. FinancialInformation 74 Item9. TheOfferandListing 74 Item10. AdditionalInformation 75 Item11. QuantitativeandQualitativeDisclosuresaboutMarketRisk 99 Item12. DescriptionofSecuritiesotherthanEquitySecurities 99 PARTII Item13. Defaults,DividendArrearagesandDelinquencies 100 Item14. MaterialModificationstotheRightsofSecurityHoldersandUseofProceeds 100 Item15. ControlsandProcedures 100 Item16. [Reserved] 101 Item16A. AuditCommitteeFinancialExpert 101 Item16B. CodeofEthics 1